Table 2.
Center 2 cohort description.
| Patient characteristics of cohorts from center 2 | ||
|---|---|---|
| Mutation prediction | Recurrence prediction | |
| Gender, n (%) | N = 238 | N = 286 |
| Male | 113 (47.5%) | 143 (50.0%) |
| Female | 125 (52.5%) | 143 (50.0%) |
| Age, years | ||
| Median | 64 | 64 |
| Range | 20-91 | 20-91 |
| Type of sampling | ||
| Tumor resection | 169 (71.0%) | 207 (72.4%) |
| Open biopsy | 23 (9.7%) | 25 (8.6%) |
| Core needle biopsy | 46 (19.3%) | 54 (18.0%) |
| Tumor site | ||
| Gastric | 127 (53.4%) | 148 (51.8%) |
| Small intestine | 55 (23.1%) | 73 (25.5%) |
| Colon or rectum | 17 (7.1%) | 23 (8.0%) |
| Others | 39 (16.4%) | 42 (14.7%) |
| Type of tumor cell | ||
| Spindle | 170(74.5%) | 220(76.9%) |
| Epithelioid | 41(17.8%) | 46(16.1%) |
| Mixt | 18(7.8%) | 20(7.0%) |
| Mutated exon | ||
| KIT exon 11 | 139 (58.4%) | 139 (48.6%) |
| KIT exon 9 | 17 (7.1%) | 17 (5.9%) |
| PDGFRA exon 18 | 32 (13.5%) | 32 (11.2%) |
| Wild type | 30 (12.6%) | 30 (10.5%) |
| Others | 20 (8.4%) | 20 (7.0%) |
| NA | 48 (16.8%) | |
| Tumor size | ||
| <5 cm | 73 (25.6%) | |
| 5–10 cm | 119 (41.7%) | |
| >10 cm | 89 (31.1%) | |
| NA | 5(1.6%) | |
| Mitotic count, per 5 mm2 | ||
| <5 | 139 (48.6%) | |
| 5–10 | 61 (21.3%) | |
| >10 | 77 (26.9%) | |
| NA | 9 (3.2%) | |
| Risk Group (AFIP) | ||
| Low risk | 86 (301%) | |
| Intermediate risk | 51 (17.8%) | |
| High risk | 130 (45.4%) | |
| NA | 19 (6.6%) | |